Epithelial Ovarian Cancer

Size: px
Start display at page:

Download "Epithelial Ovarian Cancer"

Transcription

1 Epithelial Ovarian Cancer GYNE/ONC Practice Guideline Dr. Alex Hammond Dr. Ian Kerr Dr. Akira Sugimoto Dr. Stephen Welch Kay Faroni Christine Gawlik Kerri Thornton Approval Date: This guideline is a statement of consensus of the Gynecologic Oncology Disease Site Team regarding their views of currently accepted approaches to treatment. It is not intended to replace the independent medical judgment of the physician in the context of individual clinical circumstances to determine any patient s care or treatment. 1

2 Epithelial Ovarian Cancer Gynecologic Oncology Practice Guideline Background/Incidence Communication High Risk Individuals to Consider for Genetic Counselling Clinical Assessment of a Patient with Suspected Ovarian Cancer Staging & Pathology Considerations Surgical Management Chemotherapy Management Primary Management - (Front Line) Chemotherapy Salvage chemotherapy Monitoring & Follow-up Appendix I FIGO staging Appendix II- References 2

3 Background/Incidence Ovarian Cancer consists of several histopathological types, with Epithelial Ovarian Cancer (EOC) comprising > 90% of cases. One in 70 Canadian women is affected by Ovarian Cancer. The average age of diagnosis is 56.3 years, with >60% of cases presenting with advanced disease (Cancer Care Statistics, 2008). The majority of patients will relapse, requiring further chemotherapy. Ovarian Cancer is the fifth most common cancer among women and the fifth leading cancer causing death among women. Canadian Cancer Statistics for 2008, estimate that there will be 2,500 new cases of Ovarian Cancer with 1,700 deaths. Survival is dependent on stage of cancer at initial presentation; stage I disease has a 5 year survival rate of 85%, while stage IV, a survival rate of ~10%. Communication Twenty per cent of patients with Ovarian Cancer are expected to survive five years beyond diagnosis. The vast majority of patients with Ovarian Cancer face the lifechanging issue of a chronic disease with periods of recurrence followed by stability and control of symptoms. It is paramount for patients and their key family/support persons to receive thorough and timely provider-patient communication at critical points of care, including: diagnosis, recurrence, identification of metastasis and disease progression. Critical point of care consultations should be planned in a quiet, private place and allow enough uninterrupted time. Such discussions should include hope-giving aspects of the information, the ongoing plan of care, and an assessment of the patient s understanding of their prognosis. Key aspects discussed must be accurately documented in a timely manner to facilitate appropriate transmission of information to all caregivers involved. (Refer to Cancer Care Ontario s document Provider-Patient Communication for further information). High Risk Individuals to Consider for Genetic Counselling Hereditary Ovarian Cancer is due to mutations in the BRCA 1 and BRCA 2 genes and account for 10 % of cases of all cases of epithelial Ovarian Cancer. The presence of the mutation indicates increased risk, but the individual with the mutation might never develop a cancer. Mutations in the BRCA1 gene are estimated to confer an Ovarian Cancer risk of 30% up to age 60 years, and BRCA2 gene mutations confer a risk of 27% up to 70 years. Cancer Care Ontario has created guidelines for when to refer a patient with a family history or risk factors which would indicate the need for a referral. (Refer to Cancer Care Ontario s guideline Management Options for Women with a Hereditary Predisposition to Ovarian Cancer.) 3

4 Clinical Assessment of a Patient with Suspected Ovarian Cancer Most patients with EOC present with ascites as well as a pelvic mass. These patients should be considered to have advanced EOC until proven otherwise and should be referred to a Gynecologic Oncologist at the earliest possible moment. Occasionally patients with EOC may present with an isolated pelvic mass. These requests for consultation will be reviewed to assess whether they may be best managed by a general gynaecologist. At a primary care level testing and procedures that a patient should undergo prior to referral are: History & physical Bloodwork (CBC, Chemistry, Ca125) Pelvic ultrasound and/or CT Additional investigations that may be carried out at the discretion of the specialist are: Abdo/pelvic ultrasound and/or CT Chest x-ray Percutaneous Biopsy paracentesis or pleurocentesis for malignant cytology GI evaluation ( e.g. endoscopy) if clinically indicated 4

5 SURGICAL MANAGEMENT Pelvic Mass Clinical Radiological Assessment Apparently Isolated Mass Obvious Metastatic Disease General Gyn Surgery Referral to Gyn Oncology Frozen Section Reasonable Surgical Candidate Poor Surgical Candidate (Reason) Benign Possible Serous Borderline Malignant At least borderline Surgical Evidence of Metastases Maximal Surgical Effort Core biopsy (CA-125 Cytology) No Staging required Staging Biopsies Optimal Cytoreduction Sub- Optimal Cytoreduction Diagnostic Non Diagnostic Grade I Grades II-III Systemic Treatment Algorithm Systemic Treatment Algorithm Initiate Systemic Treatment Reconsider Surgery Stage: IA Stage: IB + Systemic Treatment Algorithm Debulking as soon as Possible No Further Treatment Systemic Treatment Algorithm Completion of Chemotherapy 5

6 Algorithm for Surgical Management of the Patient Presenting with a Pelvic Mass Legend 1. Assessment of the distribution of disease should include a history, physical examination, and imaging such as CT scan or ultrasound. Evidence of Metastatic Disease may include: Clinical evidence of ascites/omental mass/intraperitoneal carcinomatosis CT evidence of ascites, peritoneal implants, omental mass Pleural effusion Elevated CA It is at the discretion of the general gynecologist as to whether or not they decide to operate on a patient with an apparently isolated pelvic mass. If, in the opinion of the general gynecologist a patient would be better served by referral to a tertiary care center for surgery by a gynecologic oncologist, then a referral can and should be made. Specific reasons why the general gynecologist is concerned about operating in the periphery should be documented. 3. In the setting of clinical or radiologic evidence of metastatic disease, the assessment regarding whether to primarily debulk upfront versus administer primary chemotherapy upfront should be by a qualified Gynecologic Oncologist prior to any treatment decisions. The standard of care has been to proceed with primary cytoreductive surgery when feasible to decrease the volume of tumor to optimal residual disease that is less than 1 cm, or no gross residual disease. The results of a large international randomized trial comparing upfront surgery to neoadjuvant chemotherapy show similar survival and decreased morbidity for women treated by neoadjuvant chemotherapy with interval debulking. In this study, optimal cytoreduction remains the single most important prognostic factor for survival, and therefore the study addresses more the timing of surgery, than the goal and principles of cytoreductive surgery. Primary debulking should remain the goal in all women presenting with complex ovarian masses suspicious for cancer. In women with evidence of advanced disease as demonstrated by peritoneal carcinomatosis or omental "cake", the benefits of primary debulking and neoadjuvant chemotherapy followed by interval debulking surgery should be evaluated in consultation with a gynecologic oncologist. Examples of reasons why primary cytoreductive surgery may not be carried out are: 6

7 Unacceptable operative risk Radiologic suspicion of unresectable intra-abdominal disease Intra-parenchymal or pleural Severe patient debilitation/malnutrition When a decision is made to treat with primary chemotherapy, the reasons why and the discussion with the patient should be documented. 4. It is acknowledged that the accuracy of frozen section can be limited. Final treatment decision will be made on the basis of final pathology reports. Notwithstanding, where the frozen section queries a Mucinous Borderline Tumor, then full staging should be carried out ( ) due to the risk of associated foci of invasive adenocarcinoma. When the frozen section suggests a Serous Borderline tumor, and the abdominal cavity appears normal, then staging ( ) need not be carried out. 5. Intraoperatively, every effort should be made to reduce the volume of residual disease to less than 1 cm. Splenectomy, diaphragmatic resection, peritoneal stripping, diaphragmatic resection may be indicated to achieve this at the discretion of the surgeon. 6. Staging Laparotomy should include: Pelviabdominal Washings Pelvic Node Dissection Para-aortic Node Dissection Omentectomy Peritoneal Biopsies 7. In order to confirm the diagnosis of intraperitoneal carcinomatosis from a primary peritoneal or ovarian origin, ideally an elevated CA-125 combined with percutaneous or transvaginal core biopsy of tissue should be documented. It is recognized that core tissue biopsies take time to organize and therefore in accepted but the reasons why core biopsy was not pursued should be documented. 8. In the setting where the CA-125 level and peritoneal cytology are not diagnostic, then careful reconsideration should be given to surgery to ascertain the diagnosis and debulk judiciously. Caution should be exercised when administering chemotherapy to patients where the diagnosis of primary peritoneal or ovarian carcinoma has been made without tissue biopsy. Metastatic malignancies from other organs have been well described to mimic ovarian carcinoma. (For example gastrointestinal tumors, breast carcinoma, lymphomas, and soft tissue sarcomas). 7

8 9. When the decision has been made to treat with primary chemotherapy, interval debulking surgery should be performed as soon as the patient is felt to be an operative candidate. The utility of interval debulking surgery decreases with increasing numbers of cycles of chemotherapy. Patients should be assessed by a qualified gynecologic oncologist after each cycle of chemotherapy for optimal timing of interval debulking surgery. 8

9 Chemotherapy Management First Line *primary surgery *primary chemotherapy Optimally Debulked Subopitimally Debulked 1 st line Chemo** 1 st line Chemo** 1 st line Chemo** Interval Debulking Surgery NED*** Persistent or Progressive Disease NED*** Persistent or Progressive Disease Chemo NED*** Follow-up Follow-up Follow-up 2 nd line Chemo Relapse 2 nd Line Chemo Relapse Relapse 2 nd Line Chemo 2 nd line Chemo 2 nd line Chemo *See Surgical Management; **as per CCO Guidelines ***NED = no evidence of disease 9

10 Chemotherapy - First line Stage Chemotherapy Comments I-IV IA, IB grade1 Evaluate patient for clinical trial where possible No treatment IA, 1B grade2 Carboplatin IV AUC 5-6 Paclitaxel* IV 175 mg/m 2 Q21days x 3 to 6 courses IA, IB grade 3 IC-IV Carboplatin IV AUC 5-6 Paclitaxel* IV 175 mg/m 2 Q21 days x 6 courses and then reassess Other options Carboplatin AUC 5-6 Day 1- paclitaxel* IV 135mg/m 2 Day 2 cisplatin IP 100mg/m 2 Day 8 paclitaxel* IP 60 mg/m 2 Q21 days x 6 courses An option but presently not available at this centre ( for optimally debulked stage III) Or IP clinical trial or local protocol Refer to CCO guidelines for further information *premedication for prevention of hypersensitivity reactions required First line chemotherapy consists of combination therapy with platinum and taxane agents. Treatment is given every 3 weeks, based on adequate blood counts and absence of toxicities. Patients with residual disease at baseline, should be optimally treated to no evaluable disease plus 2 courses. (minimum of 6 courses total) Inadequately staged disease, grade III requires full 6 courses of chemotherapy. 10

11 Chemotherapy Management Second Line Second line Supportive Care consult Platinum sensitive > 6 months Platinum resistant < 6 months Study Platin based chemotherapy Other (table 1) Study Liposomal Doxorubicin (as per CCO guidelines) Topotecan (as per CCO guidelines) Other (table 1) All above options lead here NED Progression or unacceptable toxicity Follow-up Supportive Care Change treatment modalities (Alternate treatment modalities Table 1) Responsiveness to chemo depends on bulk of tumor burden and interval from last treatment. In recurrent patients that have a long disease free interval (>18 months) a second debulking surgery should be considered. 11

12 Chemotherapy Management Second Line Platinum Sensitive Disease (> 6 months DFI) Clinical trial where possible Comments LRCP standard Carboplatin IV AUC 5-6 Paclitaxel* IV 175 mg/m 2 Other Options Docetaxel* mg/m 2 Carboplatin AUC 5-6 Gemcitabine 1000 mg/m 2 Carboplatin AUC 4 Liposomal doxorubicin 30 mg/m 2 Carboplatin AUC 5 Carboplatin AUC 5-6 Q21days x 6 courses Q21 days x 6 courses Day 1, 8 Day 1 Q 21 days Q28 days Q 21 days Platinum resistant disease (< = 6 months DFI) or Comments Progression on first line Chemotherapy Clinical trial where possible Liposomal doxorubicin 40 mg/m 2 Topotecan 1.5mg/m 2 Q28 days x 6 courses Daily x 5 days q28 days Carboplatin AUC 5-6 Docetaxel* mg/m 2 Q21 days x 6 courses Gemcitabine mg/m 2 Weekly for 3 weeks with 1 week rest *premedication for prevention of hypersensitivity reactions required 12

13 Monitoring & Follow-up The traditional purpose of regular routine follow-up is to help determine the need for and timing of further treatment. In addition it is recognized that important goals of follow up are to provide continuous education, psycho emotional support, and reassurance. This follow-up should be consistent and created with patient s quality-of-life at the forefront of consideration. Wherever possible, opportunity for follow-up should be made available locally, with an understanding that expeditious referral back to the specialist center will be made at the first sign of symptomatic recurrence. At present there is no evidence that early treatment for relapse in those who are asymptomatic offers any benefit over waiting until the symptomatic stage. In addition, follow-up visits can provoke anxiety, worry and fear in patients. Therefore, we do not recommend a particular monitoring schedule for asymptomatic patients after treatment of their Ovarian Cancer. Rather, the follow-up strategy needs to be individualized based on each patient s specific needs. For those patients who do choose to have routine monitoring at regular intervals, no optimal strategy has been defined. The following guidelines from the National Cancer Comprehensive network (NCCN) may serve as a guide for primary care physicians: Visits every two to four months for two years, then every six months for three years, then annually CA-125 level at every visit Pelvic examination, chest radiographs, and chest/abdomen/pelvic CT scan as clinically indicated CA-125 The sensitivity of an elevated CA 125 level for recurrent/persistent disease is 79 to 95 percent. Elevations in CA 125 may precede clinical or radiographic detection by three to six months. The value of early detection of recurrent Ovarian Cancer by use of CA- 125 is controversial. As mentioned above, there is no evidence that early detection of recurrent disease improves survival. CA-125 is of much more utility after symptomatic recurrence has been identified in order to assist in assessment of treatment response. Routine testing is not recommended and is an individual decision between patient and physician. Routine imaging is not recommended. CT scans should be carried out if there is clinical or CA-125 evidence for recurrent or progressive disease. 13

14 Palliative Care For patients who have documented evidence of disease progression and are transitioning to a non-curative focus on disease management; consideration should be given to a referral for Palliative Care. This provides the opportunity to maximize symptom management, goals of care, exploration of local resources, and to begin advance care planning for the future, even while active treatment is being implemented. Radiation The role of radiation therapy in the treatment of EOC is limited, but has been used in the palliative setting in select case. 14

15 Table 1 Therapeutic Options in Special Circumstances (acceptable recurrence treatment options) Common options currently accepted Carboplatin Cisplatin Etoposide Gemcitabine Liposomal doxorubicin Paclitaxel Topotecan Options in special circumstances (Options requiring special considerations?) Capecitabine Cyclophosphamide Docetaxel Radiation Tamoxifen Vinorelbine 15

16 FIGO STAGING 16

17 17

18 Resources/References Cancer Statistics Published Guidelines Scottish Intercollegiate Guidelines Network National Comprehensive Cancer Network Genetic Services in Ontario Cancer Care Ontario Practice Guidelines/Evidence-Based Series First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer PG: June 2004 Update The Optimal Chemotherapy Treatment for Women with Recurrent Ovarian Cancer (January 2000: This EBS replaces PG 4-2 Use of topotecan in pre-treated recurrent or relapsed Ovarian Cancer patients) 4-3 Version EBS: November 2006 Rewrite Adjuvant Care for Stage 1 Ovarian Cancer 4-13 PG: May

19 Resources/References The Role of Intraperitoneal Chemotherapy in the First-line Treatment of Women with Stage III Epithelial Ovarian Cancer 4-21 EBS: August Management Options for Women with a Hereditary Predisposition to Ovarian Cancer 4-4 ES: June 2004 Update Screening High Risk Women for Ovarian Cancer 4-6b ES: August Provider-Patient Communication EBS 19-2: March

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary North of Scotland Cancer Network Cancer of the Ovary Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by NOSCAN Gynaecology Cancer

More information

Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer

Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology

More information

Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths

Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1

More information

Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer

Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant

More information

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type)

Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?

More information

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the My name is Barry Feig. I am a Professor of Surgical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. I am going to talk to you today about the role for surgery in the treatment

More information

Co-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG

Co-Chairs Helen J MacKay and Diane Provencher On behalf of the OV21/PETROC Investigators CCTG, NCRI (UK), GEICO and SWOG OV21/PETROC: A Randomized Gynecologic Cancer Intergroup (GCIG) Phase II Study of Intraperitoneal (IP) vs. Intravenous (IV) Chemotherapy Following Neoadjuvant Chemotherapy and Optimal Debulking Surgery

More information

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV

FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common

More information

Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122

Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122 Ovarian cancer: recognition and initial management Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Newton Wellesley Hospital 2013

Newton Wellesley Hospital 2013 Newton Wellesley Hospital 20 Standard 4.6 Assessment and Evaluation of Treatment Planning Endometrial Cancer Each year a physician member of the cancer committee conducts a study to ensure that diagnostic

More information

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT

More information

Hitting the High Points Gynecologic Oncology Review

Hitting the High Points Gynecologic Oncology Review Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and

More information

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized

More information

Marcello Deraco M.D. Responsible Peritoneal Malignancies

Marcello Deraco M.D. Responsible Peritoneal Malignancies Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey

More information

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on? MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion

More information

Chapter 8 Adenocarcinoma

Chapter 8 Adenocarcinoma Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted

More information

Section Activity Activity Description Details Reference(s)

Section Activity Activity Description Details Reference(s) Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with Renal Cell Carcinoma AA Cancer Centre Referrals Not routine pre-op referral indicated

More information

Current state of upfront treatment for newly diagnosed advanced ovarian cancer

Current state of upfront treatment for newly diagnosed advanced ovarian cancer Current state of upfront treatment for newly diagnosed advanced ovarian cancer Ursula Matulonis, M.D. Associate Professor of Medicine, HMS Program Leader, Medical Gyn Oncology Dana-Farber Cancer Institute

More information

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment

Eligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment Bevacizumab in combination with Paclitaxel and Carboplatin - Frontline Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (This form must be completed before the first

More information

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes

EDUCATIONAL COMMENTARY CA 125. Learning Outcomes EDUCATIONAL COMMENTARY CA 125 Learning Outcomes Upon completion of this exercise, participants will be able to: discuss the use of CA 125 levels in monitoring patients undergoing treatment for ovarian

More information

Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT)

Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) Ovarian, Peritoneal, and Fallopian Tube Epithelial Cancer (OPT) ACOG District II 2 Learning Objectives At the end of this clinical presentation, obstetrician gynecologists and other women s health care

More information

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April

More information

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201

Patient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large

More information

(WG Whitfield Growden, MD; DR Diane Redington, CRNP)

(WG Whitfield Growden, MD; DR Diane Redington, CRNP) 2795 Estates Drive Park City, UT 84060 TRANSCRIPT FOR VIDEO #4: D IAGNOSIS AND TREATMENT OF GYN CARCINOSARCOMA WITH DR. WHITFIELD GROWDEN Interview, Massachusetts General Hospital January 5, 2017 Produced

More information

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO) North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO) UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Original Prepared by NMcL April 2016

More information

THORACIC MALIGNANCIES

THORACIC MALIGNANCIES THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,

More information

ACRIN Gynecologic Committee

ACRIN Gynecologic Committee ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic

More information

Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital

Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital jmisdraji@partners.org Low-grade appendiceal mucinous neoplasm (LAMN) High-grade appendiceal mucinous neoplasm (HAMN) Adenocarcinoma

More information

NICaN Testicular Germ Cell Tumours SACT protocols

NICaN Testicular Germ Cell Tumours SACT protocols Reference No: Title: Author(s) Ownership: Approval by: Systemic Anti-Cancer Therapy (SACT) Guidelines for Germ Cell Tumours Dr Audrey Fenton Consultant Medical Oncologist, Dr Vicky Coyle Consultant Medical

More information

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007

National Horizon Scanning Centre. Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer. December 2007 Aflibercept (VEGF Trap) for advanced chemo-refractory epithelial ovarian cancer December 2007 This technology summary is based on information available at the time of research and a limited literature

More information

Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy

Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Stephanie Yap, M.D. University Gynecologic Oncology Northside Cancer Institute Our Learning Objectives Review survival rates,

More information

Radiation Oncology MOC Study Guide

Radiation Oncology MOC Study Guide Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)

More information

Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies

Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:

More information

COME HOME Innovative Oncology Business Solutions, Inc.

COME HOME Innovative Oncology Business Solutions, Inc. Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment

More information

Epithelial ovarian cancer

Epithelial ovarian cancer Scottish Intercollegiate Guidelines Net work 75 Epithelial ovarian cancer A na tion al clinical guideline 1 Introduction 1 2 Screening and the role of prophylactic oophorectomy 3 3 Diagnosis 6 4 Surgical

More information

Gynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer

Gynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy

More information

It is a malignancy originating from breast tissue

It is a malignancy originating from breast tissue 59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast

More information

Prof. Dr. Aydın ÖZSARAN

Prof. Dr. Aydın ÖZSARAN Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid

More information

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer

GYNECOLOGIC MALIGNANCIES: Ovarian Cancer GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss

More information

Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer

Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal

More information

Breast Cancer Breast Managed Clinical Network

Breast Cancer Breast Managed Clinical Network Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive

More information

Management of Ovarian Cancer

Management of Ovarian Cancer Management of Ovarian Cancer Version FINAL Release date 15/07/2011 Authors Mr. Kerryn Lutchman Singh Dr Gianfilippo Bertelli Dr Rachel Jones Review date 15/7/2013 1 2 Table of Contents Foreword... 4 Introduction...

More information

receive adjuvant chemotherapy

receive adjuvant chemotherapy Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer

More information

Ovarian cancer: clinical practice the Arabic perspective

Ovarian cancer: clinical practice the Arabic perspective Lead Group Log Ovarian cancer: clinical practice the Arabic perspective Experience of Hôtel-Dieu de France University Hospital (Beirut, LEBANON) in supraradical surgery for ovarian cancer David ATALLAH

More information

Enterprise Interest None

Enterprise Interest None Enterprise Interest None Cervical Cancer -Management of late stages ESP meeting Bilbao Spain 2018 Dr Mary McCormack PhD FRCR Consultant Clinical Oncologist University College Hospital London On behalf

More information

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management. Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician

More information

Endometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines

Endometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology

More information

LAPAROSCOPY and OVARIAN CANCER

LAPAROSCOPY and OVARIAN CANCER LAPAROSCOPY and OVARIAN CANCER J. DAUPLAT Clermont-Ferrand France UNIVERSITÉ D'AUVERGNE CLERMONT 1 1 - PROPHYLACTIC OOPHORECTOMY 2 - DIAGNOSIS 3 - EARLY STAGES : STAGING 4 - ADVANCED STAGES - ASSESSMENT

More information

Surveillance report Published: 17 March 2016 nice.org.uk

Surveillance report Published: 17 March 2016 nice.org.uk Surveillance report 2016 Ovarian Cancer (2011) NICE guideline CG122 Surveillance report Published: 17 March 2016 nice.org.uk NICE 2016. All rights reserved. Contents Surveillance decision... 3 Reason for

More information

TOC NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence,

More information

NCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17

NCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17 OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay

More information

Clinical Management Guideline for Breast Cancer

Clinical Management Guideline for Breast Cancer Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:

More information

Index. Note: Page numbers of article titles are in boldface type.

Index. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.

More information

4:00 into mp3 file Huang_342831_5_v1.mp3

4:00 into mp3 file   Huang_342831_5_v1.mp3 Support for Yale Cancer Answers comes from AstraZeneca, providing important treatment options for women living with advanced ovarian cancer. Learn more at astrazeneca-us.com. Welcome to Yale Cancer Answers

More information

MEDICAL PRIOR AUTHORIZATION

MEDICAL PRIOR AUTHORIZATION MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Carcinoma of the Fallopian Tube

Carcinoma of the Fallopian Tube 119 Carcinoma of the Fallopian Tube APM HEINTZ, F ODICINO, P MAISONNEUVE, U BELLER, JL BENEDET, WT CREASMAN, HYS NGAN and S PECORELLI STAGING Anatomy Primary site The Fallopian tube extends from the posterior

More information

Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review: Version No. 1.1 Supercedes 1.0 Links to other policies

Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review: Version No. 1.1 Supercedes 1.0 Links to other policies Reference No: Title: Author(s) Ownership: Approval by: Operational Date: Systemic Anti-Cancer Therapy (SACT) Guidelines for Peritoneal Mesothelioma Professor Richard Wilson (Consultant/Chair in Cancer

More information

Gynaecological Oncology Unit Lead

Gynaecological Oncology Unit Lead Learning Outcomes: Gynaecological Oncology Unit Lead To develop knowledge and skills required by an individual to undertake the role as the Gynaecologial Oncology Unit Lead. Gynaecological Cancers Knowledge

More information

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings. Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year

More information

Clinical Trials. Ovarian Cancer

Clinical Trials. Ovarian Cancer 1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric

More information

Index. B Bilateral salpingo-oophorectomy (BSO), 69

Index. B Bilateral salpingo-oophorectomy (BSO), 69 A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell

More information

Ovarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress?

Ovarian Cancer. Disclosure. Ovarian Statistics Educational Objectives. The State of Ovarian Care in the US Why aren t we making more progress? Esteemed Physician Humanitarian Distinguished Citizen Disclosure Ovarian Cancer The State of Ovarian Care in the US Why aren t we making more progress? Dr. Goff has indicated that she has no relevant financial

More information

Dr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant Medical Oncologist

Dr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant Medical Oncologist Title: Systemic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer Author(s) Ownership: Approval by: Operational Date: Dr Sarah Mc Kenna, Consultant Medical Oncologist and Dr Joanne Millar, Consultant

More information

PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC

PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC PROGNOSTIC FACTORS AND FIRST LINE CHEMOTHERAPY IN AOC Giorgia Mangili RUF ginecologia oncologica medica IRCCS San Raffaele Milano mangili.giorgia@hsr.it STANDARD CHEMOTHERAPY The standard chemotherapy

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND

More information

Interactive Staging Bee

Interactive Staging Bee Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment

More information

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)

More information

Cervical Cancer Guidelines L and SC Network July Introduction:

Cervical Cancer Guidelines L and SC Network July Introduction: Cervical Cancer Guidelines L and SC Network July 2018 Introduction: There was a total number of 442 cases of cervix cancer diagnosed in Lancashire and South Cumbria Cancer Network in the period 2005 2009

More information

Triage of Ovarian Masses. Andreas Obermair Brisbane

Triage of Ovarian Masses. Andreas Obermair Brisbane Triage of Ovarian Masses Andreas Obermair Brisbane Why Triage? In ovarian cancer, best outcomes for patients can be achieved when patients are treated in tertiary centres by a multidisciplinary team led

More information

Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa

Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal chemotherapy: where are we going? A. Gadducci Pisa Intraperitoneal Chemotherapy (IP) in advanced ovarian cancer (EOC): Rationale The spread of disease is often limited to the peritoneal

More information

Triple Negative Breast Cancer: Part 2 A Medical Update

Triple Negative Breast Cancer: Part 2 A Medical Update Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is

More information

B Breast cancer, managing risk of lobular, in hereditary diffuse gastric cancer, 51

B Breast cancer, managing risk of lobular, in hereditary diffuse gastric cancer, 51 Index Note: Page numbers of article titles are in boldface type. A Adenocarcinoma, gastric. See also Gastric cancer. D2 nodal dissection for 57 70 Adjuvant therapy, for gastric cancer, impact of D2 dissection

More information

LCA Gynaecological Cancer Clinical Guidelines

LCA Gynaecological Cancer Clinical Guidelines LCA Gynaecological Cancer Clinical Guidelines July 2014 LCA GYNAECOLOGICAL CANCER CLINICAL GUIDELINES Contents Introduction... 5 Executive summary... 6 1 The Structure of Gynaecology Oncology Services...

More information

Gynaecological Oncology Cases

Gynaecological Oncology Cases Gynaecological Oncology Cases 1. Tamoxifen and the endometrium 2. Cancer and the older woman Dr Julie M Lamont Consultant Gynaecological Oncologist Epworth Freemasons Hospital 21 st April 2015 Mrs FS 66

More information

Staging and Treatment Update for Gynecologic Malignancies

Staging and Treatment Update for Gynecologic Malignancies Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths

More information

Anshuma Bansal 1 Bhavana Rai

Anshuma Bansal 1 Bhavana Rai DOI 10.1007/s13224-016-0926-7 ORIGINAL ARTICLE Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional

More information

The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology

The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology The Ohio State University Approach to Advanced Ovarian Cancer Korean Society of Gynecologic Oncology April 26, 2013 Larry J. Copeland M.D. Thank You for Your Friendship! 1982 1996 2013 The Ohio State University

More information

Cancer of Unknown Primary (CUP) Protocol

Cancer of Unknown Primary (CUP) Protocol 1 Department of Oncology. Cancer of Unknown Primary (CUP) Protocol Version: Document type: Document sponsor Designation Document author [ s] Designation[s] Approving committee / Group Ratified by: Date

More information

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs

More information

Guideline for the Management of Vulval Cancer

Guideline for the Management of Vulval Cancer Version History Guideline for the Management of Vulval Cancer Version Date Brief Summary of Change Issued 2.0 20.02.08 Endorsed by the Governance Committee 2.1 19.11.10 Circulated at NSSG meeting 2.2 13.04.11

More information

Endometrial Cancer. Incidence. Types 3/25/2019

Endometrial Cancer. Incidence. Types 3/25/2019 Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy

More information

Trial record 1 of 1 for:

Trial record 1 of 1 for: Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,

More information

How to Define, Evaluate, and Identify Surgical Quality. Viewpoint of the ESGO Quality Assurance Committee

How to Define, Evaluate, and Identify Surgical Quality. Viewpoint of the ESGO Quality Assurance Committee How to Define, Evaluate, and Identify Surgical Quality Viewpoint of the ESGO Quality Assurance Committee Giovanni Aletti, MD European Institute of Oncology Milan, Italy The best interest of the patient

More information

Ovarian cancer in elderly women

Ovarian cancer in elderly women Ovarian cancer Ovarian cancer in elderly women Claire FALANDRY, Michel FABBRO, Olivier GUERIN, Jean-Emmanuel KURTZ, Anne LESOIN. Problem Background Population on the rise and extremely heterogeneous Delayed

More information

OVARIAN CANCER CLINICAL TRIALS

OVARIAN CANCER CLINICAL TRIALS OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking

More information

Cancer of the ovary, fallopian tube, and peritoneum

Cancer of the ovary, fallopian tube, and peritoneum DOI: 10.1002/ijgo.12614 FIGO CANCER REPORT 2018 Cancer of the ovary, fallopian tube, and peritoneum Jonathan S. Berek 1, * Sean T. Kehoe 2 Lalit Kumar 3 Michael Friedlander 4,5 1 Stanford Women s Cancer

More information

Practice of Medicine-1 Ovarian Cancer Clinical Correlation

Practice of Medicine-1 Ovarian Cancer Clinical Correlation Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by

More information

Ovarian Tumors. Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center

Ovarian Tumors. Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center Ovarian Tumors Andrea Hayes-Jordan MD FACS, FAAP Section Chief, Pediatric Surgery/Surgical Onc. UT MD Anderson Cancer Center Case 13yo female with abdominal pain Ultrasound shows huge ovarian mass Surgeon

More information

Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus

Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre

More information

North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma

North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document

More information

Ovarian Cancer Quality Performance Indicators

Ovarian Cancer Quality Performance Indicators Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland This is an Official

More information

Ovarian Cancer Audit Comparative Annual Report 01/01/ /12/2009

Ovarian Cancer Audit Comparative Annual Report 01/01/ /12/2009 SE Scotland Cancer Network SCAN AUDIT Ovarian Cancer Audit Comparative Annual Report 01/01/2009 31/12/2009 S E Scotland Cancer Network (SCAN) (Excluding Dumfries and Galloway) NHS Borders NHS Fife NHS

More information

Ovarian cancer. Quick reference guide. Issue date: April The recognition and initial management of ovarian cancer

Ovarian cancer. Quick reference guide. Issue date: April The recognition and initial management of ovarian cancer Issue date: April 2011 Ovarian cancer The recognition and initial management of ovarian cancer Developed by the National Collaborating Centre for Cancer About this booklet This is aquick reference guide

More information

OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary)

OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary) 1 OVARIAN CANCER Updated July 2015 by: Dr. Jenny Ko (PGY 5 Medical Oncology Resident, University of Calgary) Source: UpToDate 2015, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze

More information

Torisel (temsirolimus)

Torisel (temsirolimus) Torisel (temsirolimus) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 11/1/2017 POLICY A. INDICATIONS The indications below

More information

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease Refer back to original requester with this paperwork and review previous

More information

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram Proposed All Wales Vulval Cancer Guidelines Dr Amanda Tristram Previous FIGO staging FIGO Stage Features TNM Ia Lesion confined to vulva with

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles

More information